Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
MGNX

MGNX - MacroGenics Inc Stock Price, Fair Value and News

4.12USD-0.17 (-3.96%)Market Closed

Market Summary

MGNX
USD4.12-0.17
Market Closed
-3.96%

MGNX Stock Price

View Fullscreen

MGNX RSI Chart

MGNX Valuation

Market Cap

258.0M

Price/Earnings (Trailing)

-11.1

Price/Sales (Trailing)

5.95

Price/Free Cashflow

-2.27

MGNX Price/Sales (Trailing)

MGNX Profitability

Return on Equity

-21.89%

Return on Assets

-9.36%

Free Cashflow Yield

-44.13%

MGNX Fundamentals

MGNX Revenue

Revenue (TTM)

43.4M

Rev. Growth (Yr)

-62.83%

Rev. Growth (Qtr)

-15.07%

MGNX Earnings

Earnings (TTM)

-23.2M

Earnings Growth (Yr)

-37.31%

Earnings Growth (Qtr)

-13.28%

Breaking Down MGNX Revenue

Last 7 days

-16.4%

Last 30 days

-5.5%

Last 90 days

-73.2%

Trailing 12 Months

-32.7%

How does MGNX drawdown profile look like?

MGNX Financial Health

Current Ratio

3.63

MGNX Investor Care

Shares Dilution (1Y)

1.28%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202443.4M000
2023165.3M152.5M121.1M58.7M
202271.7M66.9M93.0M151.9M
2021108.1M118.6M116.0M77.4M
202068.2M77.9M77.4M104.9M
201965.1M56.8M54.8M64.2M
2018133.3M108.9M84.5M60.1M
2017108.3M124.8M141.3M157.7M
201698.6M96.4M94.1M91.9M
2015104.4M101.9M98.2M100.9M
201462.2M59.1M57.2M47.8M
201353.9M48.8M52.9M58.0M
201258.9M60.5M62.2M63.8M
201100057.2M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MacroGenics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 20, 2024
siegel jay philip
acquired
-
-
4,500
-
May 20, 2024
ferrante karen jean
acquired
-
-
4,500
-
May 20, 2024
jackson scott thomas
acquired
-
-
4,500
-
May 20, 2024
chhabra meenu
acquired
-
-
4,500
-
May 20, 2024
liu margaret
acquired
-
-
4,500
-
May 20, 2024
heiden william k
acquired
-
-
4,500
-
May 20, 2024
hurwitz edward
acquired
-
-
4,500
-
May 20, 2024
stump david c
acquired
-
-
4,500
-
May 20, 2024
o'brien federica f.
acquired
-
-
4,500
-
Apr 04, 2024
peters jeffrey stuart
acquired
204,850
4.82
42,500
senior vp and general counsel

1–10 of 50

Which funds bought or sold MGNX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.36
106,683
175,683
0.02%
May 17, 2024
Ikarian Capital, LLC
new
-
4,683,420
4,683,420
0.51%
May 16, 2024
COMERICA BANK
new
-
648
648
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
378
609,534
705,898
-%
May 16, 2024
JANE STREET GROUP, LLC
added
419
4,871,150
5,571,860
-%
May 15, 2024
Bellevue Group AG
added
0.13
50,946,600
146,697,000
2.24%
May 15, 2024
ARMISTICE CAPITAL, LLC
reduced
-47.51
-8,654,640
35,328,000
0.47%
May 15, 2024
Pennant Investors, LP
unchanged
-
223,380
644,736
0.16%
May 15, 2024
VOLORIDGE INVESTMENT MANAGEMENT, LLC
new
-
352,029
352,029
-%
May 15, 2024
DARK FOREST CAPITAL MANAGEMENT LP
new
-
175,050
175,050
0.03%

1–10 of 44

Are Funds Buying or Selling MGNX?

Are funds buying MGNX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MGNX
No. of Funds

Unveiling MacroGenics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 04, 2024
millennium management llc
5.1%
3,209,974
SC 13G
May 21, 2024
millennium management llc
4.3%
2,704,716
SC 13G
Feb 14, 2024
t. rowe price investment management, inc.
9.1%
5,639,994
SC 13G
Feb 14, 2024
armistice capital, llc
7.37%
4,572,000
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
6.5%
4,053,077
SC 13G/A
Feb 13, 2024
bb biotech ag
16.0%
9,929,963
SC 13G/A
Feb 13, 2024
vanguard group inc
6.95%
4,309,394
SC 13G/A
Jan 24, 2024
blackrock inc.
9.9%
6,140,349
SC 13G/A
Oct 30, 2023
ra capital management, l.p.
6.1%
3,764,871
SC 13G
Feb 14, 2023
bb biotech ag
14.5%
8,929,963
SC 13G/A

Recent SEC filings of MacroGenics Inc

View All Filings
Date Filed Form Type Document
Jun 04, 2024
SC 13G
Major Ownership Report
May 24, 2024
4/A
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading
May 23, 2024
4
Insider Trading

Peers (Alternatives to MacroGenics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

MacroGenics Inc News

Latest updates
Yahoo News Australia30 hours ago
Simply Wall St12 Jun 202403:01 pm
Genetic Engineering & Biotechnology News12 May 202407:00 am
InvestorPlace10 May 202407:00 am

MacroGenics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-15.1%9,10410,72010,39713,13624,49673,09941,73426,00711,10114,14715,66230,75716,88152,69118,25320,25713,68225,19218,74110,5939,662
Costs and Expenses4.6%62,85460,07445,89958,09862,92261,11766,68967,81577,73972,38368,64971,03668,17454,86154,38867,56759,12763,84756,68563,56257,279
  S&GA Expenses17.1%14,70912,56012,40913,69213,52713,67215,35513,66916,25315,58317,16115,23415,03612,5619,73210,21610,23311,89011,83312,12210,219
  R&D Expenses-2.8%46,02947,35130,13143,22945,87245,65448,19151,74461,43855,85349,82355,78053,12142,30044,65657,35148,89451,95744,85251,44047,060
Interest Expenses-1,133--774656----------------
Net Income-13.3%-52,190-46,07217,55457,469-38,00912,802-24,813-41,304-66,443-58,022-52,886-39,935-51,272-2,087-36,043-46,885-44,724-30,396-44,631-31,767-45,017
Net Income Margin-247.6%-0.54*-0.15*0.41*0.05*-0.55*-0.79*-2.05*-3.27*-3.03*-2.61*-1.26*-1.09*---------
Free Cashflow-64.4%-47,102-28,657-35,745-2,375-13,19228,927-10,226-50,172-59,111-55,684-16,928-47,757---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-16.8%248298340306343280195218271335392426435379374328265313351384415
  Current Assets-19.4%203251291255289222148168218280335367375313310260195240276288335
    Cash Equivalents-20.4%80.0010190.0010922410984.0021.0047.0012319118921818120219793.00126157180239
  Inventory2.2%1.001.001.001.001.001.001.003.005.004.004.006.006.00--------
  Net PPE-2.5%21.0022.0023.0024.0027.0030.0032.0034.0036.0038.0039.0039.0040.0042.0041.0044.0046.0048.0050.0052.0055.00
Liabilities-2.5%14214614613423413872.0076.0093.0096.0010110785.0083.0083.0080.0075.0082.0096.0089.0094.00
  Current Liabilities-0.6%56.0056.0051.0045.0046.0049.0050.0051.0067.0075.0069.0070.0053.0051.0050.0046.0040.0045.0058.0050.0052.00
Shareholder's Equity-30.4%106153194172109142123142178240291319351296292248191231255294321
  Retained Earnings-4.7%-1,154-1,102-1,056-1,074-1,131-1,093-1,106-1,081-1,040-973-915-863-823-771-769-733-686-642-611-567-535
  Additional Paid-In Capital0.5%1,2611,2551,2501,2451,2401,2351,2291,2241,2181,2131,2071,1811,1731,0671,061981877872866861855
Shares Outstanding0.8%63.0062.0062.0062.0062.0062.0061.0061.0061.0060.0059.0059.00---------
Float-100.0%-323---181---1,600-----1,500---830-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-62.8%-45,643-28,037-35,246-2,089-12,83329,320-9,422-49,161-57,696-54,309-14,795-45,690-29,036-5,533-25,677-36,546-44,142-38,044-17,388-48,838-30,000
  Share Based Compensation27.4%5,5534,3594,7904,3914,8334,7415,1235,3005,2745,4126,3586,0705,2865,2575,8325,0964,4915,4905,3984,8843,799
Cashflow From Investing-36.1%24,79438,822-33,525-113,47628,095-5,78871,94623,039-18,482-13,553-2,61713,818-34,257-16,075-43,28141,00710,5647,626-6,372-10,120-70,492
Cashflow From Financing-9.2%24827349,91159.00100,1181,359-26337.0080018,9732,346100,6581,10274,06399,01516229737.00633119,005
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MGNX Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Revenues$ 9,104$ 24,496
Costs and expenses:  
Cost of product sales270113
Cost of manufacturing services1,8463,410
Research and development46,02945,872
Selling, general and administrative14,70913,527
Total costs and expenses62,85462,922
Loss from operations(53,750)(38,426)
Interest and other income2,6931,073
Interest and other expense(1,133)(656)
Net loss(52,190)(38,009)
Other comprehensive income (loss):  
Unrealized gain (loss) on investments(29)13
Comprehensive loss$ (52,219)$ (37,996)
Net income (loss) per common share:  
Basic net loss per common share (in usd per share)$ (0.84)$ (0.61)
Diluted net loss per common share (in usd per share)$ (0.84)$ (0.61)
Weighted average common shares outstanding:  
Basic weighted average common shares outstanding (in shares)62,290,53861,809,817
Diluted weighted average common shares outstanding (in shares)62,290,53861,809,817
Collaborative and other agreements  
Revenues:  
Revenues$ 1,449$ 16,686
Product sales, net  
Revenues:  
Revenues4,8613,490
Government agreements  
Revenues:  
Revenues358283
Contract Manufacturing  
Revenues:  
Revenues2,2763,615
RevenueFromRoyalityAgreementsMember  
Revenues:  
Revenues$ 160$ 422

MGNX Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 80,355$ 100,956
Marketable securities103,882128,849
Accounts receivable7,21910,367
Inventory, net1,2481,221
Prepaid expenses and other current assets9,8719,946
Total current assets202,575251,339
Property, equipment and software, net21,29621,847
Right-of-use asset23,22923,846
Other non current assets1,1851,386
Total assets248,285298,418
Current liabilities:  
Accounts payable10,6946,443
Accrued expenses and other current liabilities18,14824,239
Deferred revenue22,83721,651
Lease liabilities4,0853,775
Total current liabilities55,76456,108
Deferred revenue, net of current portion56,18259,243
Lease liabilities, net of current portion29,92730,196
Other non current liabilities258258
Total liabilities142,131145,805
Stockholders' equity:  
Common stock, $0.01 par value -- 125,000,000 shares authorized, 62,560,502 and 62,070,627 shares outstanding at March 31, 2024 and December 31, 2023, respectively626621
Additional paid-in capital1,260,5051,254,750
Accumulated other comprehensive loss(35)(6)
Accumulated deficit(1,154,942)(1,102,752)
Total stockholders' equity106,154152,613
Total liabilities and stockholders' equity$ 248,285$ 298,418
MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEmacrogenics.com
 INDUSTRYBiotechnology
 EMPLOYEES357

MacroGenics Inc Frequently Asked Questions


What is the ticker symbol for MacroGenics Inc? What does MGNX stand for in stocks?

MGNX is the stock ticker symbol of MacroGenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MacroGenics Inc (MGNX)?

As of Tue Jun 18 2024, market cap of MacroGenics Inc is 258.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers. The fair value of MacroGenics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MacroGenics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MacroGenics Inc a good stock to buy?

The fair value guage provides a quick view whether MGNX is over valued or under valued. Whether MacroGenics Inc is cheap or expensive depends on the assumptions which impact MacroGenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGNX.

What is MacroGenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, MGNX's PE ratio (Price to Earnings) is -11.1 and Price to Sales (PS) ratio is 5.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGNX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MacroGenics Inc's stock?

In the past 10 years, MacroGenics Inc has provided -0.157 (multiply by 100 for percentage) rate of return.